<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778425</url>
  </required_header>
  <id_info>
    <org_study_id>201602-QILU</org_study_id>
    <nct_id>NCT02778425</nct_id>
  </id_info>
  <brief_title>The Treatment of Hepatocirrhosis and Portal Hypertension</brief_title>
  <official_title>The Treatment of Gastroesophageal Varices Accompanied With Splenomegaly or Hypersplenism of Hepatocirrhosis and Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanjing Gao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinan Military General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compare the efficiency of partial splenic embolization +endoscopical therapy with
      endoscopical therapy alone in gastroesophageal variceal haemorrhage accompanied with
      splenomegaly or hypersplenism of hepatocirrhosis and portal hypertension treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic therapy is the mature treatment of gastroesophageal variceal haemorrhage and PSE
      is an effective method for treatment of the hypersplenism and portal hypertension. Existing
      researches show that endoscopic therapy + PSE is more effective than endoscopic therapy alone
      in prevention of esophageal varices bleeding recurrence in the patients with liver cirrhosis.
      However, there is few articles which proved long-term effectiveness of endoscopic therapy +
      PSE, it needs further research on this issue. This study compares the efficiency of partial
      splenic embolization +endoscopic therapy with endoscopic therapy alone in the treatment of
      gastroesophageal variceal haemorrhage accompanied with splenomegaly or hypersplenism in the
      patients with hepatocirrhosis and portal hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrent rate of gastroesophageal varices</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rehaemorrhage ratio</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">404</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Primary prevention-1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Endoscopic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary prevention-2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>beta blockers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary prevention-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic therapy+PSE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control of acute bleeding-1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Endoscopic therapy+ somatostatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control of acute bleeding-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic therapy+ somatostatin+PSE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary prevention-1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Endoscopic therapy+ beta blockers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary prevention-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic therapy+ PSE+beta blockers</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PSE</intervention_name>
    <description>Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches of diseases.It has been demonstrated to effectively increase hematologic indices in cirrhotic patients with splenomegaly. This is particularly valuable amongst those cirrhotic patients who are not viable candidates for splenectomy.</description>
    <arm_group_label>Primary prevention-3</arm_group_label>
    <arm_group_label>Control of acute bleeding-2</arm_group_label>
    <arm_group_label>Secondary prevention-2</arm_group_label>
    <other_name>Partial Splenic Embolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At the risk of gastroesophageal variceal hemorrhage; Acute gastroesophageal variceal
             hemorrhage;Haematemesis and/or melena result in gastroesophageal variceal haemorrhage
             of liver cirrhosis in the past.

          -  Splenomegaly or hypersplenism acting as thrombocytopenia (PLT &lt; 75000 cells/mm^3).

          -  Consent form must be signed by patients or their guardians before entering the test.

        Exclusion Criteria:

          -  History of liver surgery or spleen surgery and liver cancer.

          -  Existence of gastrointestinal endoscopic therapy contraindication;Hemorrhagic shock
             has not be corrected;Hepatic encephalopathy.

          -  Sinus bradycardia, bronchial asthma, chronic obstructive pulmonary disease, heart
             failure, low blood pressure, atrioventricular block, insulin dependent diabetes,
             peripheral vascular disease, liver function Child - Pugh class C.

          -  Pregnant women and nursing mothers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanjing Gao Yanjing Gao, PhD.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital,Shandong Universty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanjing Gao Yanjing Gao, PhD.MD</last_name>
    <phone>86-18560086087</phone>
    <email>gaoyanjing@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology,Qilu Hospital,Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanjing Gao , PhD.MD</last_name>
      <phone>86-18560086087</phone>
      <email>gaoyanjing@sdu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Yanjing Gao</investigator_full_name>
    <investigator_title>Vice presidengt of Department of Gastroenterology of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>partial splenic embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

